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Abstract
To date there are 9 known diseases caused by an expanded polyglutamine repeat, with the most prevalent being
Huntington’s disease. Huntington’s disease is a progressive autosomal dominant neurodegenerative disorder for which
currently no therapy is available. It is caused by a CAG repeat expansion in the HTT gene, which results in an expansion of a
glutamine stretch at the N-terminal end of the huntingtin protein. This polyglutamine expansion plays a central role in the
disease and results in the accumulation of cytoplasmic and nuclear aggregates. Here, we make use of modified 29-O-methyl
phosphorothioate (CUG)n triplet-repeat antisense oligonucleotides to effectively reduce mutant huntingtin transcript and
protein levels in patient-derived Huntington’s disease fibroblasts and lymphoblasts. The most effective antisense
oligonucleotide, (CUG)7, also reduced mutant ataxin-1 and ataxin-3 mRNA levels in spinocerebellar ataxia 1 and 3,
respectively, and atrophin-1 in dentatorubral-pallidoluysian atrophy patient derived fibroblasts. This antisense
oligonucleotide is not only a promising therapeutic tool to reduce mutant huntingtin levels in Huntington’s disease but
our results in spinocerebellar ataxia and dentatorubral-pallidoluysian atrophy cells suggest that this could also be applicable
to other polyglutamine expansion disorders as well.
Citation: Evers MM, Pepers BA, van Deutekom JCT, Mulders SAM, den Dunnen JT, et al. (2011) Targeting Several CAG Expansion Diseases by a Single Antisense
Oligonucleotide. PLoS ONE 6(9): e24308. doi:10.1371/journal.pone.0024308
Editor: Joseph Charles Glorioso, University of Pittsburgh School of Medicine, United States of America
Received April 28, 2011; Accepted August 4, 2011; Published September 1, 2011
Copyright:  2011 Evers et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The research in this study was financed by the Center for Biomedical Genetics (The Netherlands) and Agentschap NL (The Netherlands). The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Judith C.T. van Deutekom and Susan A.M. Mulders report being employed by Prosensa BV. Prosensa BV holds a patent on the use of
AONs to reduce CAG and GTG repeat containing transcripts and may (ultimately) benefit from the application of the submitted information. The LUMC
does not have any patents on the reported area and has no financial relationship with Prosensa in the field of triplet expansion diseases, nor foresees to
benefit otherwise from the use of the reported information. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and
materials.
* E-mail: w.vanroon@lumc.nl
Introduction
Polyglutamine (polyQ) diseases are a group of disorders caused
by CAG triplet repeat expansions in the coding region of the
genome. The disease causing proteins in these polyQ diseases are
very different, but in each case the expanded stretch of glutamines
results in a toxic-gain-of function of the protein and this leads to
neurodegeneration. To date, a total of 9 polyQ disorders have
been described: dentatorubral-pallidoluysian atrophy (DRPLA),
Huntington’s disease (HD), spinal bulbar muscular atrophy
(SBMA), and spinocerebellar ataxias (SCA1, 2, 3, 6, 7, and 17)
[1,2]. Of these polyQ disorders, HD and SCA3 have the highest
prevalence worldwide [3]. The expanded repeats in these polyQ
diseases are unstable resulting in anticipation; a more severe and
earlier onset of disease in following generations [4]. There is an
inverse correlation of disease onset and polyQ length in the
protein; the longer the CAG repeat, the earlier the age of onset of
the disease [1]. Protein aggregates are found in the nucleus and
cytoplasm of cells, indicating that protein misfolding is a common
feature of these disorders. Currently no treatment is available to
delay onset or even slow progression of polyQ diseases.
In HD, the expanded CAG repeat is located in the first exon of
the HTT gene on chromosome 4p16. The expanded CAG
transcript is translated into a mutant huntingtin (htt) protein with
an expanded polyQ tract at the N-terminus. Patients with 39 or
more CAG repeats will develop the disease, whereas people with
35 to 38 repeats show reduced penetrance [5]. The disease is
characterized by motor, psychiatric and cognitive impairments
and the typical age of onset lies between 30 and 50 years [6]. The
major neuropathology occurs in the striatum but degeneration is
seen throughout the brain when the disease progresses. Various
other proteins have been found to co-localize with htt aggregates,
i.e. TATA box binding protein (TBP), CREB binding protein
(CBP) and several molecular chaperones [7–10]. When the
mutation for HD was found, htt was a protein of unknown
function but extensive research over the past decade has revealed
numerous functions for htt. Also many affected cellular processes
have been identified in HD, such as transcriptional de-regulation,
mitochondrial dysfunction, and impaired vesicle transport [3,11].
SCAs are genetically and clinically distinct autosomal dominant
CAG-expansion diseases, numbered by the order of gene
description. Patients with SCA exhibit cerebellar degeneration
resulting in ataxia and oculomotor deficits, often followed by
general brain atrophy [12,13]. The first SCA identified, SCA1, is
caused by a CAG repeat expansion of 41 or more in exon 8 of the
ATXN1 gene [3]. ATXN1 is translated into the 98 kDa protein
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metabolism [14]. Mutated ataxin-1, by entering the nucleus,
causes cellular dysfunction [15]. In SCA3, the expanded CAG
repeat is located in exon 10 of the ATXN3 gene which is translated
into mutant ataxin-3 [16]. Patients develop the disease when the
number of CAGs exceed 51, while there is reduced penetrance
when the number of repeats is between 45 and 51 [17]. The 42
kDa ataxin-3 protein is suggested to be involved in proteasomal
degradation and transport of ubiquitinated proteins [18]. DRPLA
is a rare autosomal dominant disorder, characterized by dementia,
ataxia, chorea, myoclonic epilepsy, and psychiatric disturbances.
The disease is caused by a CAG repeat expansion in exon 5 of the
ATN1 gene, which encodes the 200 kDa atrophin-1 protein.
Atrophin-1 is a known transcriptional co-regulator although its
exact function is not well understood [19]. Patients with a repeat of
49 or more glutamines will develop the disease [20].
Most therapeutic strategies under investigation for polyQ
disorders are aimed at counteracting one of the many cellular
processes that are altered due to expression of the mutant protein.
For instance, in all of these neurodegenerative diseases the
formation of fragmented protein products by proteolytic cleavage
is an important step in the pathogenic process [3]. It has been
shown that altering proteolysis of the mutant htt protein can be
beneficial, as an HD mouse model lacking the caspase 6 cleavage
site had reduced neuronal dysfunction and neurodegeneration
[21]. Reducing mutant polyQ protein levels and thereby inhibiting
all downstream toxic effects would be much more effective than
targeting a single cellular process. One way to achieve this would
be to enhance the degradation of mutant polyQ proteins through
activation of the proteasome [22] or through upregulation of the
autophagic pathway [23]. Another strategy would be to inhibit the
formation of mutant polyQ proteins by gene silencing or transcript
degradation [24]. RNAi is increasingly used as a potential
therapeutic tool to reduce expression of target transcripts [25].
RNAi is an endogenous cellular defense mechanism against
exogenous viral components and is also involved in transcriptional
regulation [26]. Specific knock down of target sequences is
achieved by introducing exogenously modified oligonucleotides
(e.g. short hairpin RNA (shRNA) and short interfering RNA
(siRNA)) that bind to the target transcript, which is subsequently
degraded or its translation blocked. Recently an siRNA targeting
both normal and mutant htt was found to be well-tolerated in wild-
type rats [27]. However, endogenous htt expression is important
for normal cellular function, as underlined by the finding that
conditional knockout of murine htt in forebrain and testis resulted
in loss of function and progressive neurodegeneration [28]. Total
loss of the endogenous htt homolog in a Drosophila HD model
expressing the human first exon of the HTT gene with 93 Qs
enhanced the HD pathogenesis [29]. These studies show that a
specific reduction of mutant htt levels, leaving as much wild type
htt protein as possible, would be the optimal outcome of a therapy
aimed at htt knockdown. Specific reduction of the mutant htt
transcript was shown by allele-specific siRNAs directed against a
single nucleotide polymorphism (SNP) in htt exon 50 [30]. In a
recent study on the cleavage of triplet repeat hairpins by
ribonuclease dicer it was shown that an siRNA with 7 consecutive
CUG nucleotides specifically reduced the expression of the mutant
htt transcript containing 44 CAG repeats in HD human fibroblasts
[31]. Although off-target effects and interference with endogenous
RNAi processes remains to be assessed [32], these results are
encouraging.
Another RNA based therapy approach to knock down gene or
protein expression is the use of single stranded antisense
oligonucleotides (AONs). One of the most promising examples
of AON treatment in a neurodegenerative disease is aimed at
amyotrophic lateral sclerosis (ALS). In ,2% of ALS patients, the
disease is caused by a mutation in Superoxide dismutase 1 (SOD1)
[33]. Continuous intraventricular infusion of AONs successfully
down regulated SOD1 mRNA and protein levels in the brain and
significantly slowed disease progression in an animal model of ALS
[34]. A clinical trial is currently ongoing in ALS patients with
SOD1 mutations and results are expected this year [35].
For glutamine-expansion disorders, peptide nucleic acid (PNA)
and locked nucleic acid (LNA) antisense oligomers targeting CAG
repeats have been used to reduce expanded HD and SCA3
transcripts in vitro [36–39]. However, although PNA transfection
efficiently reduced mutant protein levels with very long glutamine
expansions, the reductions on polyQ lengths that occur most
frequently in the HD patient population were less pronounced
[38,39]. In the current we make use of 29-O-methyl (29OMe)
modified RNA AONs with a phosphorothioate (PS) backbone
carrying different CUG numbers. We examine the effect of
(CUG)n AONs on mRNA level in cell lines derived from HD,
SCA1, SCA3, and DRPLA patients with CAG expansions that
occur most frequently in the patient population. A significant
reduction in expanded transcript levels was found in patient
derived fibroblast from HD, SCA1, SCA3, and DRPLA.
Furthermore a significant reduction of mutant htt protein was
seen in the HD cells. For htt, a reduction in wild-type htt transcript
levels was observed as well, but this reduction was less pronounced
than for the mutant transcript. Lowering the AON concentration
increased the specificity for the mutant transcript. These results
show that one single antisense oligonucleotide could be a
promising therapeutic treatment for all polyQ disorders.
Results
(CUG)7 AON shows most pronounced reduction of HTT
transcript levels
Patient-derived human fibroblasts were transfected with AONs
with 3, 7 and 12 consecutive CUGs ((CUG)3, (CUG)7, and
(CUG)12, respectively) and total RNA was isolated after 48 hours.
In the HTT gene the glutamine repeat consists of a CAG stretch,
followed by one CAA and a final CAG triplet. The HD cell line
GM04022 contained a (CAG)n CAA CAG repeat with n=18 and
44. As a control fibroblasts cell line FLB73 was used where n=17
and 21. To avoid influences of CAG repeat length, reductions in
total HTT mRNA levels were measured by quantitative PCR
(qPCR) with primers within the CAG containing exon but
amplifying a transcript fragment upstream of the repeat (Table
S1). The most significant reduction in total HTT transcript of
81% (64%) in the HD and 76% (64%) in the control fibroblasts
was found after (CUG)7 treatment (Fig. 1). (CUG)12 transfection
resulted in a significant reduction of total HTT transcript of 78%
(65%) in the HD and 61% (618%) in the control cell line. The
(CUG)3 did not show significant reduction of HTT mRNA levels.
The (CUG)7 AON was selected for further testing since it was the
shortest AON resulting in the most significant reduction in HTT
mRNA levels.
Reduction of mutant HTT mRNA levels in HD cells after
(CUG) 7 treatment
Since regular htt expression is important for normal cellular
function, our approach is to lower mutant htt protein levels, while
maintaining sufficient levels of normal protein. To examine the
effect of (CUG)7 treatment on both HTT transcripts an allele-
specific PCR with primers flanking the CAG repeat was
performed in quadruplo (Fig. 2a). The mutant transcript was
Targeting of CAG-Expanded Transcripts
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in (CUG)7 treated cells compared to controls, while normal
transcript was reduced to a lesser extent with 43% (632%)
(Fig. 2b). Treatment of the control cell line with (CUG)7 showed
a reduction for both alleles of 21% (638%) and 40% (638%)
respectively.
We repeated this experiment in duplo in patient-derived Epstein
Barr Virus transformed control and HD lymphoblasts (Fig. 2c).
(CUG)7 transfection of the HD cell line gave a reduction of the
mutant transcript of 53% (610%), while only a small decrease of
22% (611%) for the normal transcript was detected (Fig. 2d).N o
apparent reduction in the control cell line was found (data not
shown).
Reduction of mutant htt protein levels in a HD cell line
after (CUG)7 treatment
Since mRNA levels of the HTT transcript were substantially
reduced after treatment with (CUG)7, in both experiments, we
investigated htt protein levels (Fig. 3a). Antibody 4C8 can be
used to detect total htt protein [40], while antibody 1C2
specifically recognizes the expanded polyQ tract [41]. Patient-
derived human fibroblasts were transfected and protein isolated
(see Materials and Methods). 96 hours after first treatment of HD
fibroblasts with 100 nM (CUG)7 4C8 antibody showed a clear
reduction of 54% (634%) in htt protein level, while a less
pronounced reduction of 16% (628%) was observed in the control
fibroblasts (Fig. 3a and data not shown). With 1C2 antibody a
significant reduction of 58% (616%) of mutant htt protein was
seen in the HD fibroblasts following 100 nM (CUG)7 treatment
(Fig. 3b). Thus, reduction of mutant htt protein was more
pronounced than normal htt.
(CUG)7 AON efficiency is concentration dependent
To test if (CUG)7 AON concentration is related to efficacy,
various AON concentrations were used to transfect HD and
control fibroblasts. Lab-on-a-Chip analysis (Fig. 4a and b)
showed a reduction of mutant HTT with an IC50 value between
2.5 nM and 5 nM (Fig 4b). At 10 nM (CUG)7 the mRNA
expression of mutant HTT was reduced by 89% (65%), whereas
normal HTT transcript was reduced by 38% (69%) in the HD
fibroblasts. HTT mRNA reduction was less pronounced for both
alleles (16% (66%) and 36% (65%)) in the control cells,
suggesting that at lower concentrations the (CUG)7 AON is more
specific at reducing HTT transcripts with expanded CAG repeats
(Fig 4a).
AON directed against the CAG repeat reduces mutant
ataxin-3 levels
Since CAG repeat expansions are a hallmark of several
neurodegenerative disorders, we tested the molecular efficacy of
our AON approach to reduce the expression of other genes as
well. SCA3 patients have a CAG triplet repeat expansion in the
ATXN3 gene, we examined the effect of (CUG)7 treatment in
patient-derived SCA3 fibroblasts with a CAG CAA (CAG)n repeat
where n=18 and 72. As for htt, the (CUG)7 treatment reduced the
transcript from the expanded ataxin-3 allele, while reduction in
transcript levels from the normal allele was less pronounced
(Fig. 5a).
PCR with primers amplifying a product containing the CAG
repeat in ATXN3 showed a significant 97% (61%) down
regulation of mutant ATXN3 after both 10 nM and 100 nM
(CUG)7 AON transfection (Fig. 5b). The wild type allele was
reduced by respectively 27% (617%) and 33% (66%) by 10 nM
and 100 nM after (CUG)7 AON treatment.
Reduction on other expanded CAG transcripts by (CUG)7
treatment
We next tested SCA1 and DRPLA fibroblasts. Allele-specific
PCRs with primers flanking the CAG repeat were performed to
examine the effect of (CUG)7 treatment in both the normal and
mutant allele. The mutant ataxin-1 (ATXN1) transcript was
decreased by 89% (614%) in 100 nM (CUG)7 treated SCA1 cells
compared to control transfections (Fig. 6a and c), while the
normal transcript was not reduced. (The SCA1 and DRPLA cell
lines served as each other’s control.) Mutant atrophin-1 (ATN1) in
DRPLA was also reduced after 100 nM (CUG)7 treatment by
98% (62%), whereas there was only a 30% (66%) reduction in
the normal allele (Fig. 6b and d).
(CUG)7 does not affect other endogenous CAG-enclosing
transcripts
The human genome contains several proteins that contain polyQ
tracts, usually encoded by a combination of CAG and CAA triplets.
Most of these transcripts are essential for normal cellular function
[42] so reducing those transcripts could impair normal cellular
function. To verify whether other uninterrupted CAG repeat
containing transcripts were affected, 5 other transcripts were
selected after a BLAST search: androgen receptor (AR), ataxin-2
(ATXN2), glutaminase (GLS), TBP, and zinc finger protein 384
(ZNF384). For the cells used in the present study the exact CAG
tract length of these 5 transcripts was first determined by Sanger
sequencing (Table 1). Primers for qPCR were designed within the
CAGcontainingexon but amplifying a fragment downstream of the
CAG repeat in the transcript (Table S1). For technical reasons
primers for ATXN2 were designed upstream of the CAG repeat.
All tested CAG-enclosing transcripts were unaffected by
100 nM (CUG)7 treatment (Fig. 7), including the AR transcript
that contained CAG repeats of 21 and 23 CAGs. Endogenous
ataxin-3 (with 17:18 Qs) and TBP (37:38 Qs) protein levels were
unaffected by 100 nM (CUG)7 treatment (Fig. 8). From the
above results we can conclude that (CUG)7 does not significantly
Figure 1. Number of CUGs of AON influences the reduction of
HTT transcript levels. Total RNA was isolated 48 hours after
transfection. Quantitative RT-PCR was used to measure HTT mRNA
levels in control and HD fibroblasts after treatment with 100 nM (CUG)3,
(CUG)7, (CUG)12 AON, 100 nM non-htt specific h40AON2 (Control AON),
transfection agent only (Mock II), or non-transfected cells (Mock I, not
included in this figure). ACTB and RPL22 are used as reference genes.
The expression level of Mock I transfections are set to 100%. For all
transfections n=6 and *** P,0.001).
doi:10.1371/journal.pone.0024308.g001
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decrease endogenous polyQ-containing protein levels.
Discussion
The present study shows that an AON targeting CAG repeats
and consisting of 7 CUGs significantly reduces protein and RNA
levels of mutant htt in patient-derived fibroblast cell lines. This
reduction was also seen, but to a lesser extends with (CUG)12 but
not with (CUG)3. Although there was also a reduction of normal
HTT transcript levels, the results show a preferential allele specific
reduction of mutant HTT in patient derived HD cells and this
allele specificity was improved when AON concentration was
lowered from 100 nM to 10 nM.
Furthermore, other non-expanded CAG-containing transcripts
that were investigated were not affected by (CUG)7 treatment.
There was no reduction after (CUG)7 treatment of the AR
transcript that contained the longest tested uninterrupted CAG
repeat, namely 21 and 23 CAGs. Normal HTT that contained 17
and 21 CAG repeats did show a reduction after (CUG)7 treatment,
suggesting that there are other factors besides the number of
consecutive CAG triplets that determine (CUG)7 efficacy.
The results with mutant ATXN1, ATXN3, and ATN1
confirmed the specificity of (CUG)7 for transcripts with an
expanded CAG tract in SCA1, 3, and DRPLA patient derived
cells, respectively. Our results suggest that (CUG)7 could be
effective in reducing expanded CAG repeat containing transcripts
in all polyQ diseases.
Figure 2. Effect of (CUG)7 AON on HTT mRNA levels in HD patient derived cell lines 48 hours after transfection. Cells were transfected
with 100 nM (CUG)7, non-htt specific h40AON2 (Control AON), transfection agent only (Mock II), or non-transfected cells (Mock I). (a) Agarose gel
analysis of the HTT transcript with primers flanking the CAG repeat of control (FLB73) and HD (GM04022) fibroblasts treated with various AONs.
Transfection with (CUG)7 shows a decrease of the upper band, representing the transcript from the mutant allele. The lower band, representing the
normal HTT transcript, is also reduced, but to a lesser extent. Control cells treated with (CUG)7 only show a slight reduction compared to the control
transfections. PCR products with primers for ACTB were used as loading control. gDNA was taken along to control for the PCR reaction over the CAG
repeat. (b) Lab-on-a-Chip analysis of HTT transcripts after (CUG)7 treatment in a HD fibroblast cell line. The mutant transcript, with 44 CAGs, is
significantly reduced by 83% after (CUG)7 treatment, compared to transfection controls. The normal HTT transcript with 18 CAGs is reduced by 43%.
Expression levels are corrected for loading differences with ACTB. The mRNA level of the Mock I transfection was set on 100% (* P,0.05, *** P,0.001,
n=4). (c) Agarose gel analysis of HTT transcripts after (CUG)7 treatment in EBV transformed control and HD human lymphoblasts. After transfection
with (CUG)7 the mutant HTT transcript with 45 CAGs is decreased compared to the Mock transfection. No changes in intensity of the HTT transcripts
from the control lymphoblasts are seen after (CUG)7 treatment. (d) Lab-on-a-Chip analysis of HTT transcripts after PS57 treatment of human HD
lymphoblasts. Mutant HTT transcript is reduced by 46% after (CUG)7 treatment, whereas the normal HTT allele shows an 11% reduction. (n=2)
doi:10.1371/journal.pone.0024308.g002
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while regular htt expression is important for normal cellular
function. Knockout of the homologous htt mouse gene was found to
be early embryonic lethal [43] and previous studies have shown that
approximately 50% of htt protein level is required to maintain cell
functionality [28,44–46]. In addition, increased clearance of mutant
htt protein by autophagy in a Drosophila model and blockage of
mutant htt in a conditional knock-out mouse model of HD resulted
in a reduction in aggregates and an ameliorated phenotype [47,48].
Reductionofmutant proteinlevelswilltherefore mostlikelyresultin
amelioration of the toxic HD phenotype but total knockdown of htt
protein expression would not be advantageous [49].
For other polyQ disorders the role of wild-type polyQ proteins
in adult brain is still poorly understood. In a SCA3 Drosophila
model expressing normal and mutant human ataxin-3, loss of
normal ataxin-3 contributed to neurodegeneration [50]. In
contrast, non allele-specific reduction of endogenous ataxin-3
was not found to be detrimental in rodents [51,52]. Ataxin-1
knockout mice resulted in cerebellar transcriptional changes
resembling SCA1 pathology, suggesting a neuroprotective role of
normal ataxin-1 [53]. In contrast, atrophin-1 knockout mice were
viable and did not show a clear phenotype [54], suggesting that
non allele-specific reduction of both alleles in DRPLA is not
harmful. Future research is necessary to determine the signifi-
Figure 3. (CUG)7 AON reduces mutant htt protein levels in HD patient fibroblast cell lines. Cells were transfected with 10 nM and 100 nM
(CUG)7, non-htt specific h40AON2 (Control AON), or non-transfected cells (Mock I). (a) Western blot of control (FLB73) and HD (GM04022) fibroblasts
treated with (CUG)7 and controls. Total (4C8) and mutant (1C2) htt protein expression is reduced 72 hours after treatment with (CUG)7. No mutant htt
could be detected in the control fibroblasts with 1C2. b-actin is used as loading control. (b) Mutant htt protein levels in HD (GM04022) fibroblasts
after 100 nM (CUG)7 transfection were quantified by ImageJ software. A significant reduction of 58% of mutant htt protein was seen after (CUG)7
transfection as compared to control transfections (* P,0.05, n=2). Mutant protein levels of Mock I transfection were set to 100%.
doi:10.1371/journal.pone.0024308.g003
Figure 4. Effect of various (CUG)7 AON concentrations on HTT mRNA expression. Cells were transfected with 1–20 nM (CUG)7. PCR
products with primers flanking the CAG repeat of HTT were quantified by Lab on a Chip. (a) In the control cell line (FLB73) both alleles (17 and 21
CAGs) show a comparable concentration dependent reduction of HTT mRNA quantification after (CUG)7 transfection. (b) In HD fibroblasts (GM04022)
the mutant transcript, with 44 CAGs, shows a strong reduction of mutant HTT mRNA expression with increasing (CUG)7 AON concentrations, whereas
the normal HTT transcript with 18 CAGs is reduced to a lesser degree. Expression levels are corrected for loading differences with ACTB and mRNA
levels of the Mock I transfections were set on 100% (* P,0.05, ** P,0.01, n=4).
doi:10.1371/journal.pone.0024308.g004
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function and the importance of AON-mediated allele-specific
transcript reduction.
Several papers have shown allele-specific silencing of mutant
htt with single nucleotide polymorphism (SNP)-specific siRNAs
[30,55]. Indeed HD patients carry different SNPs, requiring the
development of at least five different siRNAs, to target 75% of
the European and United States HD population [56,57].
However, the advantage of the approach described in the
current paper is that it requires only 1 AON to treat all HD
patients and would be applicable in other polyQ diseases.
Furthermore, siRNAs are double stranded oligonucleotides and
these have been described to cause off-target effects by the sense
strand, [58] as well as striatal toxicity [32,59]. In addition, RNA
interference is an endogenous process; addition of siRNAs might
cause toxicity due to an overload of the endogenous system.
Recently, nucleic acids conjugates, with different chemistries
than the AONs used in the current study, were used for allele-
specific silencing of mutant htt. PNAs consisting of 1 guanine,
followed by 6 CTGs, complementary to the CAG repeat, were
found to specifically reduce mutant htt and ataxin-3 protein
levels in patient-derived cells [37,38]. Although the reduction in
protein levels by PNA transfection was highly efficient with very
long stretches of CAGs, there was only a minor decrease when
the number of CAG repeats that occur most frequently in the
patient population was targeted [38,39]. Testing a variety of
modifications resulted in oligonucleotides with a thymine (T)
LNA nucleotide at every third base (LNA(T)) and 29O,49O-C-
ethyl nucleic acid (cET) which show higher selectivity (2.9 and
3.7 fold) for mutant alleles with 41 CAG repeats [36].
AONs are a promising therapeutic tool, as was recently shown
by phase I and phase I/II clinical trials in Duchenne muscular
dystrophy (DMD) boys carrying specific deletions in the DMD
gene [60]. Local and systemic (subcutaneous) delivery of a specific
29OMe modified AON induced exon 51 skipping in the DMD
gene on transcript level allowing the synthesis of novel, internally
deleted, but likely (semi-) functional, dystrophin proteins without
clinically apparent adverse events [61]. AONs have also been used
Figure 5. (CUG)7 AON reduces mutant ATXN3 mRNA expression in patient-derived fibroblasts. Cells were transfected with 10 or 100 nM
(CUG)7, non-htt specific h40AON2 (Control AON), transfection agent only (Mock II), or non-transfected cells (Mock I). (a) Agarose gel analysis with
primers flanking the CAG repeat in the ATXN3 transcript of control (FLB73) and SCA3 (GM06151) fibroblasts after (CUG)7 treatment. After transfection
with (CUG)7 the upper band, representing the mutant ATXN3 transcript, is greatly decreased in intensity, while the lower band, representing the wild-
type transcript, is only slightly reduced. b-actin was used as loading control. (b) Lab-on-a-Chip analysis of ATXN3 transcripts after 10 nM and 100 nM
(CUG)7 treatment in a SCA3 (GM06151) fibroblast cell line. The mutant transcript, with 72 CAGs, is significantly reduced by 97% after (CUG)7
treatment, compared to transfection controls. The normal ATXN3 transcript with 18 CAGs is reduced by 27% and 33% after 10 nM and 100 nM (CUG)7
AON treatment, respectively. Expression levels are corrected for loading differences with b-actin. The mRNA level of the Mock I transfection was set
on 100% (* P,0.05, ** P,0.01, n=2).
doi:10.1371/journal.pone.0024308.g005
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(GM13716) patient derived fibroblasts were transfected with 10 and100 nM (CUG)7, 10 nM non-httspecific h40AON2 (Control AON), transfection agent
only (Mock II), or non-transfected cells (Mock I). (a) Agarose gel analysis with primers flanking the CAG repeat in the ATXN1 transcript. After transfection
with both 10 nm and 100 nM (CUG)7 the upper band, representing the mutant ATXN1 transcript, is greatly decreased in intensity, while the lower band,
representing the wild-type transcript, is not reduced. b-actin was used as loading control. (b) Agarose gel analysis with primers flanking the CAG repeat
in the ATN1 transcript. After transfection with both 10 nM and 100 nM (CUG)7, the upper band representing the mutant ATN1 transcript, is greatly
decreased in intensity, while the lower band representing the wild-type transcript, is not reduced. b-actin was used as loading control. (c) Lab-on-a-Chip
analysis of ATXN1 transcripts in SCA1 cells after control AON and 10 nM (CUG)7 treatment. The mutant transcript, with 72 CAGs, is significantly reduced
by 89% after (CUG)7 treatment, compared to transfection controls. The normal ATXN1 transcript with 27 CAGs is not reduced. (d) ImageJ analysis of
ATN1 transcripts in DRPLA cells after control AON and 10 nM (CUG)7 treatment. The 66 CAGs containing mutant ATN1 transcript is significantly reduced
by 98% after (CUG)7 treatment, while normal ATN1 transcript with 16 CAGs is not significantly reduced by 30%. Expression levels are corrected for
loading differences with b-actin. The mRNA level of the Mock I transfection was set on 100% (* P,0.05, ** P,0.01, n=3).
doi:10.1371/journal.pone.0024308.g006
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be taken up by neurons when delivered into the cerebral lateral
ventricles. As treatment for ALS 29-O-methoxyethyl modified
deoxynucleotides infused intraventricularly were found to reduce
both SOD1 transcript and protein levels in rats and rhesus
monkeys, which resulted in a slower disease progression [34].
Similarly modified oligonucleotides for spinal muscular atrophy
(SMA) resulted in putative therapeutic levels in all regions of the
spinal cord after intrathecal infusion in non-human primates [62].
The exact mechanism by which the AONs are used in the
current study to reduce transcript levels and why they show both
an allele and gene preference is not known. This selective repeat-
length dependent reduction was also seen in myotonic dystrophy
type 1 after (CAG)7 AON treatment [63]. Since 29OMe PS
modified AONs are nuclease and RNase H resistant, RNase H-
induced cleavage or RISC mediated degradation of dsRNA is not
likely to be involved [63]. Another explanation could be RNase-
independent translational blocking by (CUG)7 AON binding to
the transcript, preventing binding or steric blockage of the
ribosomal units. However, translational blocking is not likely to
be involved since htt transcript levels are also reduced [38].
Reduction of transcript levels are not thought to be caused by
interference of the (CUG)7 AON during cDNA synthesis. Addition
of (CUG)7 AON just prior to the mRNA before cDNA synthesis
did not result in reduced htt transcript levels (data not shown). A
more likely explanation for the allele specific effect of the (CUG)7
AON shown in the current paper could be caused by structural
differences in transcripts with normal and expanded repeats.
Expanded CAG repeats are known to from hairpin structures [64].
(CUG)7 AON binding could stabilize this CAG RNA hairpin,
resulting in selective breakdown of the mutant transcripts. Another
explanation could be that the expanded CAG repeats have a more
open structure, making them more accessible for AON binding,
thereby leading to induction of selective breakdown, resulting in a
lower mRNA expression. These two models are not mutually
exclusive and other mechanisms may as well be involved.
However, these results show that reduction of the mutant
mRNA and/or its translation are promising generic routes
towards therapy of triplet expansion diseases. Our future plans
would be unraveling the exact mechanism of the reduction of
HTT transcripts by the AON and in vivo testing of the toxicity and
delivery of the (CUG)7 in animal models of polyQ diseases.
Here we show the first evidence of a specific reduction of mutant
htt, ataxin-1 and -3, and atrophin-1 transcript levels using 29OMe
PS modified AONs that recognizes pure CAG repeat stretches,
suggesting that a single AON is potentially applicable to polyQ
neurodegenerative diseases with an expanded pure CAG repeat.
Materials and Methods
Cell culture and Transfection
Patient derived fibroblasts from HD (GM04022), SCA3
(GM06151), SCA1 (GM06927), and DRPLA (GM13716) (pur-
chased from Coriell Cell Repositories, Camden, USA); and
Table 1. Number of uninterrupted CAGs and codons that encode for glutamine in CAG repeat enclosing transcripts as determined
by Sanger sequencing and a summary of the effect of (CUG)7 treatment in those transcripts.
Transcript Name Cell Line Glutamine stretch Uninterrupted CAGs
Significant reduction after
100 nM (CUG)7 AON
Allele
1
Allele
2 Allele 1 Allele 2
AR Control 22 24 21 23 No
HD 23 24 22 23 No
ATN1 C o n t r o l 1 92 01 51 6N o
HD 12 19 8 15 No
DRPLA 20 70 16 66 Yes
SCA1 20 20 16 16 No
ATXN1 DRPLA 29 31 14 15 No
SCA1 29 52 14 37 Yes
ATXN2 Control 20 20 8 8 No
HD 20 20 8 8 No
ATXN3 Control 17 19 15 17 Yes
HD 19 23 17 21 No
SCA3 20 74 18 72 Yes
GLS Control 8 14 8 14 No
HD 7 18 7 18 No
HTT Control 19 23 17 21 Yes
HD 20 46 18 44 Yes
TBP Control 37 38 17 18 No
HD 35 36 16 17 No
ZNF384 Control 15 16 14 15 No
HD 15 16 14 15 No
Abbreviations: AR, androgen receptor; ATN1, atrophin-1; ATXN1, ataxin-1; ATXN2, ataxin-2; ATXN3, ataxin-3; GLS, glutaminase; HTT, huntingtin; TBP, TATA box binding
protein; ZNF384, zinc finger protein 384. Reduced transcripts after (CUG)7 treatment are depicted in bold.
doi:10.1371/journal.pone.0024308.t001
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LUMC) were cultured at 37uC and 5% CO2 in Minimal Essential
Medium (MEM) (Gibco Invitrogen, Carlsbad, USA) with 15%
heat inactivated Fetal Bovine Serum (FBS) (Clontech, Palo Alto
USA), 1% Glutamax (Gibco) and 100 U/ml penicillin/strepto-
mycin (P/S) (Gibco). Human Epstein Barr Virus transformed
lymphoblasts HL2.42 and HL2.93 were a kind gift from Prof. E.
Bakker (Laboratory of Diagnostic Genome Analysis (LDGA),
LUMC). Cells were cultured at 37uC and 5% CO2 in RPMI 1640
medium (Gibco), containing 15% FBS, 1% glutamax and 100 U/
ml P/S.
AON transfection was performed with 3.3 ml ExGen 500
polyethylenimine (PEI) (MBI Fermentas, Vilnius, Lithuania) per
mg AON. AON and PEI were diluted in 150 mM NaCl to a total
volume of 100 ml and mixtures were prepared according to the
manufacturer’s instruction. Four different transfection conditions
were used: 1) transfection with 1–100 nM (CUG)7, 100 nM
(CUG)3, 100 nM (CUG)12, 2) transfection with 10–100 nM
h40AON2 directed against exon 40 of the DMD gene (59- UCC
UUU CAU CUC UGG GCU C -39) (Control AON) [65], 3)
transfection without AON (Mock II), and 4) NaCl only (Mock I).
Mixtures were added to a total volume of 2 ml of medium with
5% FBS. Four hours after transfection, medium was replaced with
fresh medium and a second identical transfection was performed
24 hours after the first transfection. All AONs consist of 29-O-
methyl RNA and contain a full-length phosphorothioate backbone
(Prosensa B.V. Leiden, the Netherlands).
RNA Isolation and RT-PCR
Forty eight hours after the first transfection cells were harvested
by trypsinization and washed twice with Hanks buffered salt
solution (HBSS) (Gibco). Total RNA was isolated from the cells
using an RNeasy Mini Kit (QIAgen, Venlo, The Netherlands),
with an on-column DNase treatment for approximately 30
minutes. RNA was eluted in 50 ml elution buffer and cDNA was
synthesized from total RNA using the Transcriptor First Strand
cDNA Synthesis Kit with Random Hexamer primers at 65uC
(Roche, Mannheim, Germany).
PCR was performed using 1 ml cDNA, 10x PCR buffer with
1.5M MgCl2 (Roche), 2 mM dNTPs, 10 pmol forward primer, 10
pmol reverse primer, 1U FastStart Taq DNA Polymerase (Roche),
1 M Betaine (Sigma-Aldrich, St. Louis, USA), and PCR grade
water to a final volume of 20 ml. PCR was performed with primers
for HTT, ATXN1, ATXN3, and ATN1 (all flanking the CAG
repeat), ACTB, and RPL22 (for sequences, see Table S1). The
PCR program started with a 4 min initial denaturation at 95uC,
followed by 35 cycles of 30 sec denaturation at 95uC, 30 sec
annealing at 60uC (56uC for ATXN3), 45 sec elongation at 72uC,
Figure 7. (CUG)7 AON does not affect other CAG-containing
transcripts. Quantitative real-time PCR was used to measure androgen
receptor (AR), ataxin-2 (ATXN2), glutaminase (GLS), TATA box binding
protein (TBP), and zinc finger protein 384 (ZNF384) mRNA levels in
control and HD fibroblasts after treatment with 100 nM (CUG)7, non-htt
specific h40AON2 (Control AON), transfection agent only (Mock II), or
non-transfected cells (Mock I). All tested CAG-enclosing transcripts were
unaffected by (CUG)7 treatment. ACTB and RPL22 are used as reference
genes. The expression level of Mock I transfections were set on 100%
(n=6).
doi:10.1371/journal.pone.0024308.g007
Figure 8. (CUG)7 AON does not reduce other polyQ-containing
proteins. Western blot of control (FLB73) fibroblasts treated with
100 nM (CUG)7, non-htt specific h40AON2 (Control AON), and non-
transfected (Mock I). TATA box binding protein (TBP) and ataxin-3 are
not reduced 72 hours after treatment with (CUG)7. b-actin is used as
loading control.
doi:10.1371/journal.pone.0024308.g008
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7 min.
Lab-on-a-Chip was performed on the Agilent 2100 Bioanalyzer
(Agilent Technologies, Waldbronn, Germany), using the Agilent
DNA 1000 Kit. Expression levels were normalized for b-actin
levels and relative to transcript levels without transfection (Mock I).
The relative mutant transcript levels were analyzed using a paired
two-sided Student t test. Differences were considered significant
when P,0.05.
qPCR, Calculations and Sequencing
The qPCR was performed using 1 ml of 5x diluted cDNA, 2x
FastStart Universal SYBR Green Master mix (Roche), 2.5 pmol
forward primer, 2.5 pmol reverse primer and PCR grade water to
a total volume of 10 ml. Primer pairs for 6 transcripts containing
long uninterrupted CAG repeats were selected for qPCR by
BLAST analysis and ACTB and RPL22 were used as reference
genes. (For primer list, see Table S1). The qPCR was performed
using the LightCycler 480 (Roche). Initial denaturation was
10 min. at 95uC, followed by 45 cycles of 10 sec. denaturation at
95uC, 30 sec. annealing at 59uC and 20 sec. elongation at 72uC.
The final elongation was performed 5 min. at 72uC. Next, we
performed a melting curve analysis of all samples from 60uCt o
98uC with a ramp rate of 0.02uC per sec.
Relative expression of the transcript levels was calculated as
described previously [66]. All samples were run in triplicate on a
plate and two independent experiments were performed for each
sample. On all plates both reference genes were included to
correct for inter-plate variance.
Primer efficiencies were determined using LinRegPCR
v11.1[67] with the raw data amplification curves as input and
Mock II was used as reference. Values from the mock water
transfected cells (Mock I) were set on 100%. The relative transcript
levels were analyzed using a paired two-sided Student t test.
Differences between groups were considered significant when
P,0.05.
CAG repeats of the CAG enclosing transcripts were amplified
using primers flanking the CAG repeat (see Table S1). PCR
products were loaded on an agarose gel and bands were extracted
using the QIAquick Gel Extraction Kit (QIAgen). The purified
products were sequenced by Sanger sequencing, using the Applied
Biosystems 96-capillary 3730XL system (Life Technologies
Corporation, Carlsbad, USA) with the Applied Biosystems
BigDyeTerminator v3.1 kit.
Protein isolation and Western blotting
Cells were detached from the culture surface with a 0.5%
Trypsin/EDTA solution. After washing twice with 1x HBSS, cells
were resuspended in 200 ml ice cold lysis buffer, containing 1x
PBS, 0.4% Triton-X100, and 1 tablet Complete mini protease
inhibitor EDTA free (Roche) per 10 ml buffer. Next, samples were
sonicated 3 times for 5 seconds using ultrasound with an amplitude
of 60 at 4uC. After incubation in a head-over-head rotor at 4uC for
1 hour, the extract was centrifuged for 15 min at 10,000g and 4uC
and supernatant was isolated. Protein concentrations were
determined by the bicinchoninic acid kit (Thermo Fisher
Scientific, Waltham, USA) using Bovine Serum Albumin as a
standard. Samples were snap frozen and stored at 280uC.
Protein extracts were separated by SDS-PAGE, with 4–15%
acryl/bisacrylamide 1:37.5 separating gels and 30 mg (human
fibroblasts) of protein lysate loaded. For each sample the Spectra
Multicolor High Range Protein Ladder (Fermentas) was used as a
marker. Electrophoresis was performed for 30 min at 100V
through the stacking gel and 5 hours at 150V through the running
gel. Gels were blotted onto a polyvinylidene fluoride (PVDF)
membrane for 3 hours at 300 mA. Membranes were blocked with
1x Tris Buffered Saline +0.5% Tween 20 (TBST) containing 5%
non-fat milk powder (Profitar Plus, Nutricia, Zoetermeer, the
Netherlands). The antibodies used for detection were mouse 4C8
for htt (Eurogentec, Liege, Belgium) dilution 1:1000, mouse 1C2
specific for expanded poly glutamine stretches (Eurogentec)
dilution 1:500, mouse ataxin-3 (Eurogentec) 1:1000, rabbit TBP
(Santa Cruz Biotechnology, USA) 1:1000, and mouse b-actin,
diluted 1:5000. Secondary antibodies were goat a-mouse-horse-
radish peroxidase (Santa Cruz) and goat a-rabbit-horseradish
peroxidase (Santa Cruz), both diluted 1:10.000 in 1x TBST.
Horseradish peroxidase was activated by ECL+ reagent (GE
Healthcare, Buckinghamshire, United Kingdom) to visualize
positive staining on film.
Protein bands were quantified using ImageJ software. The
percentage of inhibition was calculated as a relative value to a non-
treated control sample and was normalized using b-actin.
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